what symptom is priority for the nurse to assess for in a patient diagnosed with hemophilia a?

Caused Hemophilia

NORD gratefully acknowledges Graça D. Almeida-Porada, MD, PhD, Professor of Regenerative Medicine, Manager Fetal Enquiry and Therapy Program, Wake Woods Institute for Regenerative Medicine, Wake Forest School of Medicine and Francesco Baudo, Dr., Hematology Section, Ospedale Niguarda, Milan, Italy, for assist in the preparation of this study.

Synonyms of Acquired Hemophilia

• acquired hemophilia A (AHA)
• caused hemophilia B (AHB)

General Give-and-take

Summary

Acquired hemophilia (AH) is a rare autoimmune disorder characterized past bleeding that occurs in patients with no personal or family history of diseases related to clotting/coagulation. Autoimmune disorders occur when the body's allowed system mistakenly attacks salubrious cells or tissue. In AH, the body produces antibodies (known equally inhibitors) that attack clotting factors, most often factor VIII. Clotting factors are specialized proteins required for the blood to clot usually. Consequently, affected individuals develop complications associated with abnormal, uncontrolled bleeding into the muscles, skin and soft tissue that tin can occur spontaneously, during surgery or following trauma. Specific symptoms tin include nosebleeds (epistaxis), bruising throughout the torso, solid swellings of congealed blood (hematomas), claret in the urine (hematuria) and gastrointestinal or urogenital bleeding. AH can potentially cause life-threatening bleeding complications in severe cases. In approximately 50% of patients, at that place is an identifiable underlying clinical condition; in the other 50%, no crusade is known (idiopathic).

Introduction

AH is different from congenital hemophilia, a group of rare genetic disorders caused past mutations in the genes encoding certain clotting factors. The main course of hemophilia is hemophilia A (archetype hemophilia), which is an X-linked disorder that mostly affects males but tin can also affect females. Information technology is acquired by deficiency or inactivation of factor VIII, the same clotting cistron that is afflicted in well-nigh individuals with AH. Although both disorders involve deficiency of the same clotting cistron, the haemorrhage design is quite different. The reason the bleeding patterns differ betwixt these disorders is not fully understood.

Curlicue back up to restore default view.

Signs & Symptoms

The symptoms of AH develop because the blood cannot clot properly. Clotting is the procedure by which claret clumps together to plug the site of a wound. Clotting factors, such as factor Eight, are specialized proteins that are essential for the blood to clot properly.

Although about ane/3 of patients do not require therapy to command bleeds, haemorrhage severity varies and more than 1/3 of patients suffer multiple bleeding episodes. Subcutaneous bleeding (ecchymoses) is the most mutual manifestation of AH followed past muscle bleeding (hematoma), gastrointestinal (melena), genitourinary (hematuria) and retroperitoneal. Intracranial hemorrhage is rare, merely can be fatal. In contrast to congenital hemophilia A, joint haemorrhage (hemarthrosis) is infrequent.

Bleeding oftentimes occurs without cause (spontaneously).Bleeding episodes are oft severe and tin go life-threatening. In some patients, delayed diagnosis and the presence of additional medical bug are frequently contributing factors to the overall severity of AH. Haemorrhage into the soft tissues tin can progress apace, potentially causing compartment syndrome, a potentially serious, painful condition characterized past increased pressure on muscles, nerves and blood vessels most frequently inside the artillery and legs, with damage due to compression of these structures.

Affected Individuals are also at risk of excessive bleeding during surgery or following trauma, fifty-fifty piffling. Genital heavy bleeding in pregnant women may occur especially after childbirth (postpartum period).

Causes

AH is an autoimmune disorder. It occurs when the immune arrangement produces antibodies that mistakenly attack good for you tissue, specifically specialized proteins known as clotting factors, most often clotting factor Eight.

The immune system normally responds to a foreign substance by producing specialized proteins called antibodies. Antibodies work past destroying strange substances directly or by coating them with a substance that marks them for destruction past white blood cells. When antibodies target salubrious tissue they may be referred to equally autoantibodies. Researchers believe that a triggering issue (such as an infection or underlying disorder) may induce the immune organization to produce autoantibodies. Autoantibodies in AH are termed inhibitors because they inhibit the function of the affected clotting factor.

AH is predominantly a disease of the elderly. In approximately 50% of the patients, no underlying disorder or triggering event tin can exist identified (idiopathic course). The remaining 50% have circumstantial disorders or conditions including autoimmune disorders such every bit lupus, rheumatoid arthritis, multiple sclerosis, Sjogren syndrome, and temporal arteritis; inflammatory bowel disease or ulcerative colitis; infections; diabetes; hepatitis; respiratory or dermatological diseases; blood (hematological) cancer or certain solid tumors. AH has also been associated with drugs such as penicillin or interferon and an clan with pregnancy has also been reported, mainly in the post-partum menstruation.

Affected Populations

AH develops in individuals with no previous history of bleeding disorder with approximately equal numbers of males and females afflicted. In the United states, the disorder is estimated to affect approximately .2-ane individuals per i,000,000/year in the general population. In the United Kingdom, the disorder is estimated to bear upon i.4 per 1,000,000/yr. However, affected individuals may go undiagnosed or misdiagnosed, making it difficult to determine the true frequency of the disorder in the general population.

Individuals of whatsoever age tin can be affected, although AH is extremely rare in children. The incidence increases with age and mostly affects elderly individuals (between threescore-80 years of age). A small increment in incidence occurs in pregnant adult female between the ages of xx-xl. AH affects individuals of all ethnic groups and has been reported worldwide. The bulk of cases involve deficiency of factor VIII (caused hemophilia A). A handful of cases have been described that involve deficiency of gene Nine (acquired hemophilia B). Although extremely rare, caused hemophilia involving other clotting factors has besides been reported.

Diagnosis

AH should exist suspected by the clinical picture and confirmed by an abnormal coagulation exam. A diagnosis should be considered in patients with a recent onset of abnormal bleeding and an isolated prolongation of the activated partial thromboplastin time (aPTT), specially the elderly and peri- and mail service-partum women.

Clinical Testing and Work-Upwardly

Routine kickoff line coagulation tests include activated fractional thromboplastin time (aPTT) and prothrombin time (PT). The two tests mensurate coagulation time of plasma, triggered past 2 different tissue factors (in aPTT fractional thromboplastin). aPTT is sensitive mainly to FVIII, FIX, FXI and XII, whereas PT is sensitive to coagulation proteins synthesized by the liver (FII, FVII, FIX, the then called "prothrombin complex" with synthesis depending on vitamin K).

Individuals with AH have an isolated prolonged aPTT, with normal PT. Tests to dominion out other causes of isolated prolonged aPTT such as not-specific inhibitors (e.g., lupus anticoagulant) or heparin therapy are as well performed.

aPTT mixing tests, carried out by mixing patient'southward plasma with normal plasma, can farther confirm the diagnosis. A mixing study differentiates genetic factor deficiencies from factor inhibitors. A sample of blood is taken and mixed with claret from a control subject. In individuals with a factor deficiency the normal plasma restores the exam value to normal; in individuals with a factor inhibitor information technology does not.

Once a gene inhibitor is established, an assay will be done to measure the activity of coagulation factors (in the majority of cases FVIII) and the titer of the inhibitor. In individuals with AHA, this volition demonstrate cistron Viii deficiency and tin can ascertain the severity (titer count) too.

Standard Therapies

Handling
Because AH is a rare disorder, most therapies used to treat affected individuals are based upon anecdotal reports or pocket-size cases series. At that place are few studies directly comparison the efficacy of specific treatments. Consequently, treatment is highly individualized.

The specific therapeutic procedures and interventions will vary, depending upon numerous factors including the specific symptoms present; the natural class of the disorder including underlying cause (if known); age and overall health (e.g., concomitant affliction), tolerance of certain medications or procedures, and personal preference; and other factors. Decisions apropos the use of detail therapeutic interventions should be made past physicians and other members of the healthcare squad in careful consultation with the patient and/or parents based upon the specifics of his or her case; a thorough discussion of the potential benefits and risks including possible side furnishings and long-term effects; patient preference; and other appropriate factors.

Spontaneous remission has been reported; in general, it may occur in postpartum cases (within a few months of delivery) and, in the cases secondary to an allergic drug reaction, normally inside a few months of stopping the offending medication. Spontaneous remission can also occur in other afflicted individuals such as those who take low titer inhibitors. The exact percentage of patients that undergo spontaneous resolution is unknown.

The management of AH focuses on the following goals: decision-making and preventing bleeding (if present or significant), eradication of the inhibitor, and treatment of the underlying disease (if applicable).

Controlling Bleeding Episodes

Bleeding may be very severe and may have a sudden onset. Therefore, prompt hemostatic control is mandatory in order to reduce morbidity and mortality. The International Recommendations state that anti-hemorrhagic treatment should be started in patients with severe bleeding in which a diagnosis of AH is confirmed, irrespective of inhibitor titer and factor 8 activity. Two approaches are bachelor: the utilise of bypassing agents (concentrates of factors that featherbed the acquired deficiency) or strategies to increase FVIII levels. The choice between these two options is based on the site and the severity of bleeding and the characteristics of each individual patient. Since hemostatic agents exercise not have a anticipated result, treatment of bleeding should be supervised by an proficient in this field and proper laboratory tests. Imaging techniques and a skillful clinical evaluation are necessary to confirm hemostatic control and haemorrhage resolution. Fibrin glue or antifibrinolytic agents may be useful in the control of local bleeding.

Bypassing agents are the recommended first-line therapy due to their rapid action and high level of effectiveness. The dosage is largely based on experience with the management of patients with FVIII inhibitors in congenital hemophilia and is generally based on the clinical assessment.

The bypassing agents presently available are recombinant activated cistron VII (rFVIIa, NovoSeven® RT, or Sevenfact) or activated prothrombin complex concentrate (aPCC or FEIBA®). None of these therapies are constructive in all individuals.

NovoSeven® RT is a genetically engineered (recombinant) version of factor VII. Because it is artificially created in a lab, it does non contain human blood or plasma and consequently, there is no gamble of blood-borne viruses or other such pathogens. NovoSeven has been well-tolerated and associated with few side effects. Hazard of thrombotic adverse effects (thrombosis) is below i% for individuals with AH. NovoSeven has been approved past the Food and Drug Administration (FDA) for use equally a bypassing agent for the handling of individuals with acquired hemophilia.

In 2020, the FDA approved Sevenfact (recombinant human coagulation factor VIIa expressed in the mammary gland of genetically engineered rabbits and secreted into the rabbits' milk) for treatment and control of bleeding in adults and adolescents age 12 and older with hemophilia A or B with inhibitors. It is presumed that Sevenfact could likewise exist used in the treatment of acquired hemophilia A, only studies take non yet been published to corroborate this assumption.

Activated prothrombin complex concentrate (aPCC) is a plasma-derived, anti-inhibitor complex that contains diverse activated clotting factors. These factors permit the drug to bypass sure steps in the formation of blood clots (including the steps that crave factor Eight). aPCC is treated to inactivate any potential viruses or similar pathogens and adverse thrombotic events are rare. The only form of aPCC currently available in the United States is FEIBA® (Fthespian eastwardight inhibitor bypassing activity).

Therapeutic modalities that allow an increase of FVIII, such as infusion of FVIII concentrate or DDAVP, that induces release of FVIII past the endothelial cells, are normally considered inadequate unless the inhibitor titer is very low (i.eastward. < v Bethesda units [BU]) and bypassing agents are not available. In 2014 The US FDA approved Obizur [Antihemophilic Factor (Recombinant), Porcine Sequence] for the treatment of bleeding episodes in adults with acquired hemophilia A (acquired Factor VIII [FVIII] deficiency).

Inhibitor Eradication

Although in some cases inhibitor tin disappear spontaneously, as long every bit the inhibitor is present, bleeding-related morbidity and mortality is significant. Therefore, therapy to eradicate the inhibitor (immunosuppression therapy) in adults is recommended to beginning immediately later on the diagnosis of AH unless clearly contraindicated. Recommendations are largely derived from ascertainment made in registries that take nerveless real life data.

In general, corticosteroids alone or in combination with cyclophosphamide are the first line therapy. No articulate difference in long-term survival was observed between these two modalities. However, individuals respond differently to immunosuppressive drugs, and what is effective in i individual may be ineffective in another. A variety of boosted immunosuppressive agents accept been used to treat caused hemophilia including cyclosporine A, azathioprine, vincristine, mycophenolate mofetil, and 2-chlorodeoxyadenosine.

Criteria for the response to treatment take not been established; nevertheless, high inhibitor titer and low FVIII level seem to be the best predictor of the response to therapy.

Relapse of AH can occur in individuals who achieve remission one time immunosuppressive therapy is stopped or if the dose is reduced. Unfortunately, considering of the associated side furnishings, long-term immunosuppressive therapy is not recommended.

Individuals with AH are encouraged to avoid activities that accept a significant risk of trauma until after inhibitor eradication.

Patients with AH will benefit from referral to a federally-funded hemophilia handling center. These specialized centers can provide comprehensive care for individuals with hemophilia and related disorders including the development of specific handling plans, monitoring and follow-up of afflicted individuals, and land-of-the-art medical intendance. Treatment at a hemophilia treatment center ensures that individuals and their family members will be cared for past a professional healthcare team (physicians, nurses, physical therapists, social workers and genetic counselors) experienced at treating individuals with hemophilia.

Investigational Therapies

Researchers have been studying the drug rituximab, an anti-CD20 monoclonal antibody, as a potential therapy for individuals with AH. This drug attacks the autoantibodies that cause the disease and has shown promising results in eradicating inhibitors in AH. The current consensus is that rituximab should be considered in patients who are resistant to first-line therapy or who cannot tolerate standard immunosuppressive therapy. However, some clinicians have farther fine-tuned recommended utilise of rituximab to permit its inclusion as starting time-line therapy in combination with prednisone for patients whose inhibitor titers are higher than v Bethesda units (BU) simply lower than 30 BU and in combination with prednisone and cyclophosphamide for patients whose titers are college than xxx. More research is necessary to determine the long-term safety and effectiveness of rituximab for the treatment of AH.

High-dose intravenous immunoglobulin has been explored as a ways to eradicate inhibitors in AH. However, near reports in the medical literature detail disappointing results. Some researchers believe that this therapy best holds promise as an offshoot treatment to other drugs or procedures that eradicate inhibitors.

Some individuals who take loftier titers of inhibitors and severe haemorrhage may undergo a procedure called plasmapheresis or immunoabsorption. These procedures are usually reserved for patients who take not responded to other handling options and are experiencing life-threatening bleeding episodes. Plasmapheresis involves removing unwanted substances from the claret. Claret is removed from the patient and the solid blood cells are separated from the liquid plasma. The patient's plasma is then replaced with donor homo plasma or albumin, which is re-transfused, along with the patient's original blood cells. The modified Bonn-Malmö Protocol (MBMP) combines immunoadsorption on columns that specifically link immunoglobulins (FVIII inhibitor) with FVIII replacement and immunosuppression and can achieve rapid and safe control of acute bleeding. Information technology is mainly implemented in Europe since immunoadsorption columns are not bachelor in the US.

Complications of immunosuppressive therapy (IST)

IST increases take a chance for infection in the already elderly, fragile population. Neutropenia (decrease of white claret cells) and sepsis are ofttimes reported and contributed to death. Other well-recognized complications of steroid therapy have been reported including raised blood carbohydrate levels, gastrointestinal ulcers, muscle disorders, and psychiatric disorders (3%).

Conclusions: Inquiry and Other Needs

AH is more than frequently encountered by the internist or emergency room doc who is most often the get-go to evaluate the patient. It is likely that AH is underdiagnosed and misdiagnosed in real-globe clinical practice, suggesting the demand to raise awareness of this disease among healthcare practitioners and to encourage referral to specialists in the management of AH. For most, AH is eminently treatable, with articulate benefits from prompt recognition and appropriate management. Both hemostatic and allowed therapy imposes considerable risks and requires close monitoring to ensure rubber. The highest priority in AH enquiry is to develop safer immunosuppressive regimens that improve survival by better balancing inhibitor eradication with the side effects of treatment.

Information on current clinical trials is posted on the Cyberspace at www.clinicaltrials.gov . All studies receiving U.S. authorities funding, and some supported by private industry, are posted on this regime web site.

For information most clinical trials existence conducted at the NIH Clinical Eye in Bethesda, Physician, contact the NIH Patient Recruitment Part:

Toll-free: (800) 411-1222
TTY: (866) 411-1010
Email:[email protected]

Some current clinical trials as well are posted on the following page on the NORD website:
https://rarediseases.org/for-patients-and-families/data-resource/news-patient-recruitment/

For information about clinical trials sponsored by private sources, in the principal, contact:
world wide web.centerwatch.com

For information about clinical trials conducted in Europe, contact:
https://www.clinicaltrialsregister.eu/

NORD Member Organizations

• Hemophilia Federation of America
  • 999 Due north Capitol St NE
  • Suite 201
  • Washington, DC 20002 USA
  • Phone: (202) 675-6984
  • Email: [email protected]
  • Website: http://www.hemophiliafed.org
• National Hemophilia Foundation
  • seven Penn Plaza
  • Suite 1204
  • New York, NY 10001 USA
  • Phone: (212) 328-3700
  • Toll-free: (800) 424-2634
  • E-mail: [electronic mail protected]
  • Website: http://www.hemophilia.org

Other Organizations

• Canadian Hemophilia Gild
  • 301-666 Sherbrooke Street W
  • Montreal, QC H3A 1E7 Canada
  • Telephone: (514) 848-0503
  • Toll-gratuitous: (800) 668-2686
  • Email: [email protected]
  • Website: http://www.hemophilia.ca
• Children's Cancer & Claret Foundation
  • 333 East 38th Street, Suite 830
  • New York, NY 10016-2745
  • Phone: (212) 297-4336
  • Email: [e-mail protected]
  • Website: http://world wide web.childrenscbf.org/
• Genetic and Rare Diseases (GARD) Information Center
  • PO Box 8126
  • Gaithersburg, MD 20898-8126
  • Phone: (301) 251-4925
  • Toll-gratuitous: (888) 205-2311
  • Website: http://rarediseases.info.nih.gov/GARD/
• Irish Haemophilia Lodge
  • Get-go Flooring
  • Cathedral Courtroom
  • Dublin, seven Ireland
  • Phone: 353016579900
  • Email: [email protected]
  • Website: http://www.haemophilia.ie/
• NIH/National Heart, Lung and Blood Plant
  • P.O. Box 30105
  • Bethesda, MD 20892-0105
  • Telephone: (301) 592-8573
  • Electronic mail: [email protected]
  • Website: http://www.nhlbi.nih.gov/
• World Federation of Hemophilia
  • 1425, boul. René-Lévesque O.
  • Bureau 1010
  • Montréal, Québec, H3G 1T7 Canada
  • Phone: (514) 875-7944
  • Email: [email protected]
  • Website: http://www.wfh.org/en/folio.aspx?pid=492

References

Journal Articles
Tiede A, Hofbauer CJ, Werwitzke South, et al. Anti-cistron Eight IgA as a potential mark of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 Study. Blood. 2016;127:2289-2297. http://www.ncbi.nlm.nih.gov/pubmed/26912467

Kruse-Jarres R, St-Louis J, Greist A, et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia. 2015;21:162-170. http://www.ncbi.nlm.nih.gov/pubmed/25623166

Tiede A, Klamroth R, Scharf RE, et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): Results from the GTH-AH 01/2010 study. Blood. 2015;125:1091-1097. http://world wide web.ncbi.nlm.nih.gov/pubmed/25525118

Borg JY, Guillet B, Le Cam-Duchez V, Goudemand J, Levesque H, Group SS. Outcome of caused haemophilia in France: the prospective SACHA (Surveillance des Motorcar antiCorps au cours de l'Hemophilie Acquise) registry. Haemophilia. 2013;nineteen:564-570. http://www.ncbi.nlm.nih.gov/pubmed/23574453

Seita I AK, Higasa S, Sawada A, Kuwahara G, Shima M. . Treatment of acute bleeding episodes in caused haemophilia with recombinant activated cistron VII (rFVIIa): analysis from 10-twelvemonth Japanese mail-marketing surveillance. J Thromb Haemost. 2013;11:119.

Baudo F, Collins P, Huth-Kuhne A, et al. Management of bleeding in caused hemophilia A: Results from the European Acquired Haemophilia (EACH2) registry. Claret. 2012;120:39-46. http://www.ncbi.nlm.nih.gov/pubmed/22618709

Collins P, Baudo F, Knoebl P, et al. Immunosuppression for caused hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Claret. 2012;120:47-55. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3390961/

Kempton CL, Abshire TC, Deveras RA, et al. Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine gene Viii, in subjects with haemophilia A. Haemophilia. 2012;xviii:798-804. http://www.ncbi.nlm.nih.gov/pubmed/22512291

Knoebl P, Marco P, Baudo F, et al. Demographic and clinical data in acquired hemophilia A: results from the European Caused Haemophilia (EACH2) Registry. J Thromb Haemost. 2012;[Epub ahead of print]. http://www.ncbi.nlm.nih.gov/pubmed/22321904

Baudo F, Caimi T, de Cataldo F. Diagnosis and treatment of acquired haemophilia. Haemophilia. 2010;sixteen:102-106. http://www.ncbi.nlm.nih.gov/pubmed/20536992

Kelesidis T, Raphael J, Blanchard East, Parameswaran R. Acquired hemophilia as the crusade of life-threatening hemorrhage in a 94-year-former man: a case report. J Med Case Reports. 2010:four:231. http://www.ncbi.nlm.nih.gov/pubmed/20670435

Huth-Kunhe A, Baudo F, Collins P, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica. 2009;94:566-575. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663620/?tool=pubmed

Franchini M, Lippi 1000. Caused factor Eight inhibitors. Blood. 2008;112:250-255. http://bloodjournal.hematologylibrary.org/content/112/two/250.full

Ma AD, Carrizosa D. Caused factor 8 inhibitors: pathophysiology and treatment. Hematology Am Soc Hematol Educ Program. 2006:432-437. http://www.ncbi.nlm.nih.gov/pubmed/17124095

Maillard H, Launay D, Hachulla E, Goudemand J, Lambert M, Morell-Dubois South, et al. Rituximab in postpartum-related acquired hemophilia. Am J Med. 2006 Jan. 119(i):86-8.

Aggarwal A, Grewal R, Dark-green RJ, Boggio L, Dark-green D, Weksler BB, et al. Rituximab for autoimmune haemophilia: a proposed handling algorithm. Haemophilia. 2005 January. eleven(i):thirteen-9.

Franchini Thou, Gandini G, di Paolantonio T, Mariani 1000. Acquired hemophilia A: a concise review. Am J Hematol. 2005;80:55-63. http://onlinelibrary.wiley.com/doi/10.1002/ajh.20390/pdf

Franchini G, Girelli D, Olivieri O, et al. Clinical heterogeneity of acquired hemophilia A: a description of 4 cases. Haematologica. 2005;90:e46-e49. http://www.haematologica.org/content/90/3/ECR16.long

Freedman J, Garvey MB. Immunoadsorption of factor Eight inhibitors. Curr Opin Hematol. 2004;11:327-333. http://world wide web.ncbi.nlm.nih.gov/pubmed/15666656

Kain S, Copeland TS, Leahy MF. Handling of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab). Br J Haematol. 2002 Nov. 119(2):578.

Wiestner A, Cho HJ, Asch As, Michelis MA, Zeller JA, Peerschke EI, et al. Rituximab in the treatment of acquired gene Eight inhibitors. Claret. 2002 Nov one. 100(9):3426-8.

Net
Grethlein SJ. Acquired Hemophilia Handling & Management. Medscape. Last update Jan 10, 2020. https://emedicine.medscape.com/commodity/211186-treatment. Accessed April 26, 2021.

Years Published

2012, 2016, 2021

The data in NORD's Rare Disease Database is for educational purposes only and is not intended to supercede the advice of a physician or other qualified medical professional.

The content of the website and databases of the National Organization for Rare Disorders (NORD) is copyrighted and may not be reproduced, copied, downloaded or disseminated, in whatsoever manner, for any commercial or public purpose, without prior written authorization and approval from NORD. Individuals may print one hard copy of an individual disease for personal use, provided that content is unmodified and includes NORD'southward copyright.

National Organization for Rare Disorders (NORD)
55 Kenosia Ave., Danbury CT 06810 • (203)744-0100

congerstrisne.blogspot.com

Source: https://rarediseases.org/rare-diseases/acquired-hemophilia/

Share this post